Assenagon Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Assenagon Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,783	Closed	-$69K	–	1438
2022 Q1	$69K	Sell	8,783 -116,330	-93%	-$799K	﹤0.01%	1389
2021 Q4	$1.05M	Buy	125,113 +112,304	+877%	+$2.06M	﹤0.01%	1014
2021 Q3	$359K	Buy	12,809 +10,218	+394%	+$327K	﹤0.01%	1121
2021 Q2	$101K	Sell	2,591 -3,230	-55%	-$132K	﹤0.01%	1167
2021 Q1	$274K	Buy	5,821 +767	+15%	+$42.3K	﹤0.01%	1118
2020 Q4	$198K	Buy	+5,054	New	+$172K	﹤0.01%	954
2020 Q3	–	Sell	-2,980	Closed	-$217K	–	1098
2020 Q2	$217K	Sell	2,980 -565	-16%	-$39.1K	﹤0.01%	1062
2020 Q1	$186K	Buy	+3,545	New	+$237K	﹤0.01%	728

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management's ABEO Position: Q2 2022 in Review

Assenagon Asset Management sold out of Abeona Therapeutics (ABEO) in Q2 2022, closing a stake of 8,783 shares — an estimated $69K sold.

Assenagon Asset Management first reported a position in ABEO in Q1 2020 and held it in 8 quarters. The position peaked at $1.05M in Q4 2021. 42 funds tracked by Wall St. Rank hold ABEO as of Q2 2022.

Assenagon Asset Management reported no remaining Abeona Therapeutics position as of Q2 2022 after selling out during the quarter.
Assenagon Asset Management sold 8,783 Abeona Therapeutics shares in Q2 2022, an estimated $69K.
Assenagon Asset Management first reported a position in Abeona Therapeutics in Q1 2020 and held it in 8 quarters.
Assenagon Asset Management's Abeona Therapeutics position peaked at $1.05M in Q4 2021.
42 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2022.

Based on Assenagon Asset Management's 13F filing for Q2 2022, filed 27 Jul 2022.